Insights

Leveraging the immunological diversity of the PentaMice® platform for COVID-19 antibody discovery

icons/content-types/white paper white paper

Biologics Discovery

Hybridoma technology is a popular method for antibody discovery, but the conventional approach of using a single inbred mouse strain for immunization fails to generate the diversity and antibody titers needed to maximize the discovery of high-quality leads. This white paper introduces an alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and highlights how Curia is leveraging it for COVID-19 antibody discovery.

Download our white paper for insights on:

  • The PentaMice platform
  • Discovering SARS-CoV-2 variant-specific antibodies
  • Discovering diverse, high-quality antibodies against SARS-Cov-2

Download the White Paper

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us
More from Curia

icons/content-types/article article

Lyophilization: Protecting and preserving biologics

Lyophilization, also known as freeze-drying, is often a crucial step in the manufacturing process of biologics drug products. Biologics are large, complex molecules used to treat various diseases, including cancer, autoimmune disorders, and rare gene...

icons/content-types/white paper white paper

Rapid discovery and characterization of monoclonal antibodies against the SARS-CoV-2 Delta spike protein

In the fall of 2021, the Delta variant of SARS-CoV-2 was the dominant strain in the US, being both more contagious than previous variants and more likely to lead to “long COVID” than subsequent Omicron variants. Here we describe the discovery and...